14th Aug 2014 12:20
LONDON (Alliance News) - Physiomics PLC said Thursday that it has signed a new contract with an unnamed pharmaceutical company, to adapt its Virtual Tumour clinical technology to model immunomodulatory agents.
The company will initially focus on making pre-clinical predictions, and said that if this is successful the project may be expanded to also adapt the the technology to immune therapies in cancer. It expects to complete the project by the end of 2014.
The project will be performed on a fee-for-service basis, the company said.
"Physiomics will benefit greatly from the experience gained building such models in this exciting area of cancer research," said Chief Executive Mark Chadwick in a statement.
Shares in Physiomics were trading up 11.3% at 0.178 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics